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Cross-disorder genetic analyses implicate dopaminergic
signaling as a biological link between Attention-Deficit/
Hyperactivity Disorder and obesity measures
Nina Roth Mota 1,2, Geert Poelmans1, Marieke Klein 1,3, Bàrbara Torrico4,5,6,7, Noèlia Fernàndez-Castillo4,5,6,7, Bru Cormand4,5,6,7,
Andreas Reif 8, Barbara Franke 1,2 and Alejandro Arias Vásquez1,2
Attention-Deficit/Hyperactivity Disorder (ADHD) and obesity are frequently comorbid, genetically correlated, and share brain
substrates. The biological mechanisms driving this association are unclear, but candidate systems, like dopaminergic
neurotransmission and circadian rhythm, have been suggested. Our aim was to identify the biological mechanisms underpinning
the genetic link between ADHD and obesity measures and investigate associations of overlapping genes with brain volumes. We
tested the association of dopaminergic and circadian rhythm gene sets with ADHD, body mass index (BMI), and obesity (using
GWAS data of N= 53,293, N= 681,275, and N= 98,697, respectively). We then conducted genome-wide ADHD–BMI and
ADHD–obesity gene-based meta-analyses, followed by pathway enrichment analyses. Finally, we tested the association of
ADHD–BMI overlapping genes with brain volumes (primary GWAS data N= 10,720–10,928; replication data N= 9428). The
dopaminergic gene set was associated with both ADHD (P= 5.81 × 10−3) and BMI (P= 1.63 × 10−5); the circadian rhythm was
associated with BMI (P= 1.28 × 10−3). The genome-wide approach also implicated the dopaminergic system, as the Dopamine-
DARPP32 Feedback in cAMP Signaling pathway was enriched in both ADHD–BMI and ADHD–obesity results. The ADHD–BMI
overlapping genes were associated with putamen volume (P= 7.7 × 10−3; replication data P= 3.9 × 10−2)—a brain region with
volumetric reductions in ADHD and BMI and linked to inhibitory control. Our findings suggest that dopaminergic
neurotransmission, partially through DARPP-32-dependent signaling and involving the putamen, is a key player underlying the
genetic overlap between ADHD and obesity measures. Uncovering shared etiological factors underlying the frequently observed
ADHD–obesity comorbidity may have important implications in terms of prevention and/or efficient treatment of these conditions.
Neuropsychopharmacology (2020) 45:1188–1195; https://doi.org/10.1038/s41386-019-0592-4
INTRODUCTION
Attention-Deficit/Hyperactivity Disorder (ADHD) is a psychiatric
disorder characterized by developmentally inappropriate and
impairing levels of inattention and/or hyperactivity and impulsiv-
ity. The prevalence of ADHD is estimated as 5.3% during
childhood/adolescence [1] and around 2.8% during adulthood
[2]. ADHD is among the most heritable psychiatric disorders, with
heritability estimates around 74% [3]. It follows a multifactorial
pattern of inheritance, where multiple genetic and environmental
factors, each of small effect, and their interplay can contribute to
its pathophysiology. A recent genome-wide association study
(GWAS) meta-analysis identified the first genome-significant
associations for ADHD [4].
High comorbidity rates are a hallmark of ADHD, further
increasing disease burden. These comorbidities include both
psychiatric and non-psychiatric (somatic) diseases and traits [5].
Among the most frequently reported comorbid somatic condi-
tions in ADHD is obesity [6]. Obesity is nowadays one of the major
health problems worldwide, resulting in a large economic burden
and significant decrease in life expectancy [7]; its prevalence
keeps rising [8]. Obesity is usually classified according to body
mass index (BMI), which is calculated as weight in kilograms
divided by the height in meters squared (kg/m2). A BMI > 25 kg/m2
signals overweight and a BMI > 30 kg/m2 is regarded as obesity,
which can be further subdivided into classes defined based on
increasing BMI [9]. The genetic contribution to obesity and related
phenotypes has been extensively studied, and heritability
estimates range from 50% up to 90% [10]. Several GWASs have
been conducted on obesity and BMI. For BMI, the most recent
GWAS meta-analysis included nearly 700,000 individuals and
identified 536 associated genomic loci [11]. A previous GWAS on
158,864 participants with BMI information compared normal
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weight individuals to those with obesity classes I, II, and III [12].
The authors concluded that associations found with categorical
phenotypes are highly overlapping with those obtained by using
BMI as a quantitative trait [12].
The reported prevalence of ADHD among adults seeking weight
loss treatment for obesity is around 27%, reaching up to 43%
when considering only those with extreme obesity (i.e., class III)
[13, 14]. This rate is over ten times higher than the prevalence of
ADHD in adults in the general population [2]. Likewise, two recent
meta-analyses show a higher than expected prevalence of
overweight and/or obesity in ADHD, both during childhood/
adolescence and adulthood, with odds ratios up to 1.55 and
strongest effects in adults [15, 16]. Importantly, the association
between ADHD and obesity was no longer significant when the
analysis was limited to participants receiving pharmacological
treatment for ADHD [15].
Specific factors underlying the comorbidity between ADHD and
obesity remain largely unknown. Recently, significant genetic
correlations between ADHD and BMI (rg= 0.21–0.26, [4, 17]) and
between ADHD and obesity (ranging from rg= 0.285 to rg= 0.338
for different obesity classes) and other obesity-related phenotypes
have been reported [4]. These findings highlight the involvement
of genetic factors in the observed epidemiological overlap
between ADHD and obesity measures and provide an entry point
for the investigation of specific biological processes involved.
In addition to clinical and genetic overlap between ADHD and
obesity measures, volumetric differences in specific brain regions
have been associated with ADHD [18] and/or obesity/BMI [19]. In
particular, volumes of putamen and nucleus accumbens are
reduced in ADHD and are negatively correlated with BMI in
the general population [18, 19]. Given that subcortical volumes
have also been shown to be heritable traits [20], one may wonder
whether shared genetic factors between ADHD and obesity
measures could also be associated with volumetric variation in
these specific subcortical brain regions.
Some candidate biological systems have been suggested to
underly ADHD comorbidity patterns, including dopaminergic
neurotransmission and circadian rhythm systems. These two
candidate mechanisms have been selected as the main focus of
a large European Union consortium aimed at studying comorbid
conditions of ADHD (CoCA; https://coca-project.eu/), of which this
study is a part.
Altered reward processing and impaired inhibitory control, key
features of ADHD, are thought to be the outcome of dysregulated
dopaminergic neurotransmission [21]. The central role of
the dopaminergic system on ADHD is further supported by the
dopamine transporter protein being the main target of methyl-
phenidate, the medication of first choice in the pharmacological
treatment of ADHD [22]. Studies in humans and animal models
have also linked disturbances in dopaminergic neurotransmission
and downstream processes to obesity [23, 24]. Overeating may
represent an attempt of obese people to compensate for their
reduced reward sensitivity [23].
Circadian rhythm-related traits (e.g., eveningness) and distur-
bances (e.g., sleep problems) have been repeatedly associated
with ADHD and/or ADHD symptoms [25]. These problems have
also been linked to BMI variation and obesity. Disrupted circadian
rhythm signaling may lead to obesity through temporal altera-
tions in eating behavior and changes in metabolic hormones [26].
Two manifestations of circadian rhythm disruption in particular,
sleeping problems (i.e., altered sleep duration) and an unstable
eating pattern (e.g., skipping breakfast and binge eating later in
the day), may mediate the observed association between ADHD
symptoms and BMI [27].
In this paper, we aimed to identify shared etiological factors
underlying the observed associations of ADHD with obesity
measures and to explore the relationship of overlapping genes
with brain volumes. Specifically, we conducted (1) candidate
gene-set association analyses and (2) genome-wide gene-based
cross-disorder(/trait) meta-analyses, from which the identified
overlapping genes were taken forward for (3.1) pathway enrich-




This study used publicly available summary statistics of GWAS of
ADHD, BMI, obesity, and selected brain volumes. These are briefly
described below, and further information is provided in Supple-
mentary Material. These studies had been approved by local ethics
committees and had obtained the required informed consents (as
described in earlier publications [4, 11, 12, 20, 28]).
The ADHD data was derived from 19,099 cases and 34,194
controls, composed by samples from the Lundbeck Foundation
Initiative for Integrative Psychiatric Research (iPSYCH) and the
Psychiatric Genomics Consortium (PGC) samples of European
ancestry [4].
For BMI, we used summary statistics from the most recent BMI
GWAS of European ancestry (N= 681,275) from the Genetic
Investigation of ANthropometric Traits (GIANT) consortium [29]
and UK Biobank [11].
For obesity, summary statistics from a GWAS from European
ancestry cohorts within the GIANT consortium on obesity class I
were used (N= 32,858 cases, N= 65,839 controls) [12]. Subjects in
that study were considered as cases for obesity class I if they had
BMI ≥ 30 kg/m2; controls had a BMI < 25 kg/m2.
Summary statistics for selected brain volumes were derived
from GWAS by the Enhancing Neuro Imaging Genetics through
Meta-Analysis (ENIGMA) consortium (N range= 10,720–10,928)
[20]. Furthermore, we used GWAS summary statistics from the UK
Biobank samples (N= 8,428) [28] for replication of significant
findings.
ADHD–BMI genetic correlation analysis
Owing to the large increase in sample size of the most recently
published GWAS meta-analysis on BMI, we conducted linkage
disequilibrium (LD) score regression analysis [30] to (re-)estimate
the genetic correlation between ADHD and BMI using summary
statistics of the largest GWASs currently available for each
phenotype. We used pre-computed LD scores based on European
samples from the 1000 Genomes Project as indicated in https://
github.com/bulik/ldsc/wiki/Heritability-and-Genetic-Correlation.
Hypothesis-driven, candidate gene-set approach
Gene-set association analyses. In order to assess the links of
dopaminergic neurotransmission and circadian rhythm pathways
with ADHD, BMI, and obesity, we assembled gene sets and tested
their associations to the individual phenotypes of interest using
the GWAS summary statistics described above. Dopaminergic
neurotransmission and circadian rhythm gene sets were
assembled based on the Kyoto Encyclopedia of Genes and
Genomes (KEGG) and the Gene Ontology (GO) databases. The final
dopaminergic (DOPA) and circadian rhythm (CIRCA) gene sets
comprised 264 and 284 unique autosomal genes, respectively.
Details on the selection of the gene sets are provided
in Supplementary Material.
Gene-set association analyses were performed using the
MAGMA software (version 1.05b [31]). We first carried out single
gene-based analyses to assess the degree of association of each
gene (i.e., gene-based P value) with each phenotype. Next, we
tested the association of each gene set, through competitive
analyses, by aggregating the gene-based P values according to
their presence (or not) in the gene sets (more detailed description
in Supplementary Material). We used a conservative Bonferroni
correction to account for the six gene-set tests (i.e., (DOPA,
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CIRCA) × ADHD, BMI, obesity); hence, the gene-set significance
P value threshold was set to 8.33 × 10−3.
Data-driven, genome-wide approach
Gene-based cross-disorder/trait meta-analyses. In addition to the
hypothesis-driven approach described above, we performed
genome-wide gene-based cross-disorder(/trait) meta-analyses by
using gene-based P values for ADHD, BMI, and obesity (obtained
as described above) and the gene meta-analysis option in the
MAGMA software (version 1.05b [31]). The weighted Stouffer’s Z
method was used to combine the Z-scores for each gene across
cohorts, with weights set to the square root of the sample size
each Z-score is based on (i.e., accounting for the fact that sample
sizes vary per single-nucleotide polymorphism (SNP)—and thus
per gene—within- and between-GWAS summary statistics). Since
we were interested in the combined effect of each gene on both
phenotypes in each pair-wise meta-analysis, only genes present in
both gene-based GWAS results were included. The gene-based
P value threshold for genome-wide significance was set to 0.05
divided by the number of genes in each gene-based meta-
analysis.
From each pair-wise gene-based cross-disorder(/trait) meta-
analysis, the genome-wide significant genes that increased
significance by at least one order of magnitude compared to
each of the original gene-based results (i.e., Pmeta-analysis < PADHD/
10 and Pmeta-analysis < P(obesity or BMI)/10) were considered as
overlapping genes and taken forward for follow-up analyses. This
measure was taken in order to avoid including genes for which
the association signal is driven solely by one of the phenotypes
being meta-analyzed, especially considering the difference in the
GWAS sample sizes.
Canonical pathway enrichment analyses. The sets of ADHD–BMI
and ADHD–obesity overlapping genes were then individually
tested for enrichment of canonical pathways using Ingenuity
Pathway Analysis (http://www.ingenuity.com; QIAGEN Bioinfor-
matics, Redwood City, CA, USA), using its default parameters and
Benjamini–Hochberg correction for multiple testing (see Supple-
mentary Material for details).
Variance explained by ADHD–BMI overlapping genes. We used
stratified LD score regression [32] in order to estimate the
proportion of the SNP heritability explained by the set of
ADHD–BMI overlapping genes in each of these phenotypes, also
testing for heritability enrichment in this set of genes. This
variation of partitioned heritability analyses compares the
proportion of SNPs (Prop.SNPs) included in the (ADHD–BMI gene
set) annotation and the proportion of the SNP heritability (Prop.
h2) accounted for by this to the total number of SNPs and total
SNP heritability. By dividing these two measures (i.e., Prop.h2/
Prop.SNPs), an enrichment value and its significance can be
calculated, jointly modeling the gene set annotation and the
“baseline model” of LD score analyses [32].
ADHD–BMI overlapping genes and brain volumes. The identified
ADHD-BMI overlapping genes were also taken forward in order to
test their association, as a gene set, with brain volumes previously
found associated with both ADHD [18] and BMI [19] by
neuroimaging studies (namely, the putamen and the nucleus
accumbens). For these analyses, we used GWAS summary statistics
of brain volumes from the ENIGMA consortium and the UK
Biobank, the latter being used as a replication sample for
significant findings (further sample details provided above and
in Supplementary Material). As exploratory analyses, we also
tested the associations of the set of ADHD–BMI overlapping genes
with those volumes previously associated with only one of these
conditions (i.e., either only ADHD or BMI). The gene-set analyses
were carried out in the MAGMA software (version 1.05b [31]), in
the same manner as described above.
RESULTS
ADHD–BMI genetic correlation
The ADHD–BMI genetic correlation was estimated as rg= 0.3157
(SE= 0.0246; P= 8 × 10−38). This is similar to estimates based on
smaller BMI data sets as well as to estimates for the obesity classes
previously reported [4, 17] and mentioned in “Introduction.”
DOPA and CIRCA gene-set associations with ADHD, BMI, and
obesity
We tested the association of two gene sets—DOPA (264 genes)
and CIRCA (284 genes)—with ADHD, BMI, and obesity. Results of
these gene-set analyses are shown in Table 1. The DOPA gene set
was significantly associated with both ADHD (P= 5.81 × 10−3) and
BMI (P= 1.63 × 10−5); the CIRCA gene set was associated with BMI
(P= 1.28 × 10−3). These results were not driven by one or few
individual genes that were highly associated with either ADHD or
BMI (Supplementary Table S1).
ADHD–BMI and ADHD–obesity gene-based meta-analyses
The gene-based cross-disorder(/trait) meta-analysis between
ADHD and BMI resulted in 1684 genome-wide significant genes,
while the one for ADHD and obesity resulted in 22 significant
genes. Of those, 211 genes for the ADHD–BMI meta-analysis and 9
genes for the ADHD–obesity meta-analysis showed an increase in
their association significance (i.e., decrease in P value) of at least
one order of magnitude compared to both individual GWASs.
These genes, which were all at least nominally significant in the
original GWASs being meta-analyzed, are listed in Supplementary
Tables S2 and S3.
The stratified LD score regression showed that the set of 211
ADHD–BMI overlapping genes explain 9.7% and 3.7% of the SNP
heritability of ADHD and BMI, respectively, yielding significant
heritability enrichment (h2_E) in this set of genes (ADHD h2_E=
8.671, P= 1.915 × 10−14 and BMI h2_E= 3.332, P= 5.036 × 10−11).
Canonical pathway enrichment analyses
Based on the 211 genes from our ADHD–BMI gene-based meta-
analysis, the enrichment analysis identified four significant
canonical pathways, as shown in Table 2. These were CREB
Signaling in Neurons, Synaptic Long Term Depression, Synaptic Long
Term Potentiation, and Dopamine-DARPP32 Feedback in cAMP
Signaling. The enrichment analysis for the nine ADHD–obesity
genes also rendered four significant canonical pathways: GABA
Receptor Signaling, Corticotropin Releasing Hormone Signaling,
Table 1. Gene-set association results of dopaminergic (DOPA) and
circadian rhythm (CIRCA) systems with ADHD, BMI, and obesity.
DOPAa CIRCAb
ADHDc 5.81 × 10−3 0.521
BMId 1.63 × 10−5 1.28 × 10−3
Obesitye 0.050 0.205
Values shown are association P values. Significant associations are
highlighted in bold
aDOPA gene-set analyses are based on 261, 245, and 248 genes from the
ADHD, BMI, and obesity GWAS summary statistics, respectively
bCIRCA gene-set analyses are based on 281, 272, and 273 genes from the
ADHD, BMI, and obesity GWAS summary statistics, respectively
cEuropean ancestry iPSYCH-PGC ADHD GWAS [4]
dGIANT-UK Biobank BMI GWAS [11]
eGIANT obesity (class I) GWAS [12]
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Dopamine-DARPP32 Feedback in cAMP Signaling, and Huntington’s
Disease Signaling (Table 3).
One pathway, the Dopamine-DARPP32 Feedback in cAMP
Signaling, was found enriched in the two analyses. In total,
proteins encoded by eight unique genes derived from our meta-
analyses operate in this canonical pathway (Tables 2 and 3).
Combining the enrichment analysis with a literature search, we
constructed a schematic representation of the Dopamine-DARPP32
Feedback in cAMP Signaling pathway, which is shown in Fig. 1 and
described in detail in Supplementary Material.
Welcome Trust participants had been included both in the
iPSYCH-PGC and the GIANT GWASs; we therefore performed a
secondary ADHD–BMI gene-based cross-disorder(/trait) meta-
analysis to address the small sample overlap between the data
sets (for further information, see Supplementary Material). Analysis
after excluding those participants from the ADHD GWAS-MA
resulted in 202 genes of interest, highly overlapping with the 211
genes from the main ADHD–BMI meta-analysis results (182
overlapping genes), where the Dopamine-DARPP32 Feedback
in cAMP Signaling pathway remained significantly associated








Feedback in cAMP Signaling
P value 4.11 × 10−5 5.68 × 10−5 2.17 × 10−4 2.19 × 10−4
P value—B-H corrected 7.95 × 10−3 7.95 × 10−3 1.53 × 10−2 1.53 × 10−2
Canonical pathway size (number of genes) 212a 188b 127c 165d
ADHD–BMI genese in the pathway 10 9 7 8
CACNA1Df,g CACNA1Df,g CREB3L3f CACNA1Df,g
CREB3L3f GNAT1 GRIA1f,g CREB3L3f
GNAT1 GRIA1f,g GRM4 CSNK1G2
GRIA1f,g GRID2 ITPR3f,g ITPR3f,g
GRID2 GRM4 PLCL1 PLCL1
GRIK5 IGF1R PPP1R3A PPP1R3A




a211 unique genes could be traced back to the NCBI 37.3 gene mapping file, where 207 of them were located in autosomes. The number of nominal genes
from this pathway and the number of genes present in the corresponding gene-based results are given as (#Nominal genes/#Genes present): ADHD—42/203;
BMI—113/194; ADHD–BMI—120/193. Number of nominal genes from this pathway that are part of the DOPA or CIRCA gene sets: DOPA—62; CIRCA—70. Of
the 211 genes found in this pathway, 110, 100, and 78 genes overlap with those in the Synaptic Long Term Depression, Synaptic Long Term Potentiation, and
Dopamine-DARPP32 Feedback in cAMP Signaling pathways, respectively
bOf the 181 genes found in the gene mapping file, 177 of them were autosomes. (#Nominal genes/#Genes present): ADHD—33/177; BMI—99/168; ADHD–BMI
—104/168. DOPA—43; CIRCA—35. Of the 181 genes found in this pathway, 67 and 61 genes overlap with those in the Synaptic Long Term Potentiation and
Dopamine-DARPP32 Feedback in cAMP Signaling pathways, respectively
cOf the 125 genes found in the gene mapping file, 123 of them were autosomes. (#Nominal genes/#Genes present): ADHD—25/122; BMI—76/113; ADHD–BMI
—79/112. DOPA—43; CIRCA—42. Of the 125 genes found in this pathway, 83 genes overlap with those in the Dopamine-DARPP32 Feedback in cAMP
Signaling pathway
dOf the 156 genes found in the gene mapping file, 155 of them were autosomes. (#Nominal genes/#Genes present): ADHD—29/154; BMI—88/143; ADHD–BMI
—91/142. DOPA—65; CIRCA—58
eGenes from the ADHD–BMI gene-based meta-analysis results, only considering genome-wide significant (at Pthreshold= 2.99 × 10
−6) genes with association P
values lower by at least one order of magnitude in the meta-analysis compared to the gene-based results of both ADHD and BMI individually
fAlso part of DOPA in the gene-set analysis
gAlso part of CIRCA in the gene-set analysis









P value 6.69 × 10−4 1.45 × 10−3 2.05 × 10−3 4.19 × 10−3
P value—B-H corrected 2.81 × 10−2 2.87 × 10−2 2.87 × 10−2 4.40 × 10−2
Canonical pathway size (number
of genes)
128 143 165 270
ADHD–obesity genesa in the
pathway









aGenes from the ADHD–obesity gene-based meta-analysis results, only considering genome-wide significant genes (at Pthreshold= 2.97 × 10
−6) with association
P values lower by at least one order of magnitude in the meta-analysis compared to the gene-based results of both ADHD and obesity individually
bAlso part of DOPA in the gene-set analysis
cAlso part of CIRCA in the gene-set analysis
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with the phenotype through the canonical pathway enrichment
analysis.
ADHD–BMI overlapping genes and brain volumes
The set of 211 ADHD–BMI overlapping genes was also used to test
the association with volumetric variation of brain structures. As
shown in Table 4, the ADHD–BMI gene set was significantly
associated with putamen volume in the ENIGMA GWAS-MA (P=
7.7 × 10−3). This association was replicated in the UK Biobank
GWAS results (P= 3.9 × 10−2). Associations with other subcortical
volumes and intracranial volume were also tested, as exploratory
analyses, and were all non-significant (Table 4).
DISCUSSION
In this paper, we aimed to uncover biological mechanisms
underlying the observed genetic associations between ADHD
and obesity measures. Based on known and self-derived genetic
correlation estimates for ADHD and BMI/obesity obtained from
the world-wide largest data sets for each phenotype, we first
applied a hypothesis-driven testing approach of two selected
gene sets (DOPA and CIRCA), which showed that the dopaminer-
gic neurotransmission system partially explains the genetic
overlap between ADHD and BMI. Our data-driven, genome-wide
approach subsequently showed that dopaminergic signaling,
specifically Dopamine-DARPP32 Feedback in cAMP Signaling,
was significantly enriched in both the ADHD–BMI and the
ADHD–obesity gene-based meta-analysis results.
Both ADHD and obesity measures have been linked to
disturbances in dopaminergic signaling. Alterations of the brain’s
executive and reward circuits—modulated by mesocortical and
mesolimbic dopamine, respectively—have been postulated as the
basis of the deficient inhibitory control and impaired reward
processing characteristics of ADHD [21]. The ability to resist the
impulse to eat desirable foods, and an appropriate reward
response to those, also require proper functioning of these
Fig. 1 Schematic representation of the Dopamine-DARPP32 Feedback in cAMP Signaling pathway. The proteins encoded by the eight
genome-wide significant genes derived from the ADHD-BMI gene-based meta-analysis results (Table 2) are contextualized and highlighted in
red in the pathway. A detailed description of the pathway in provided in Supplementary Material. For clarity and simplicity, additional proteins
in the pathway are omitted. Protein groups or complexes are shown with double margins.
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dopamine-regulated processes [23, 24]. For example, impulsive
eating, as a result of a high arousal response to a potential reward
and impaired inhibitory control, can lead to weight gain and
obesity [33]. Eating behavior is also dependent on the hypotha-
lamic homeostatic system, which comprises hormonal regulators
of energy balance—such as insulin, leptin, and gut hormones—
and controls hunger, satiety, and adiposity [23]. Increasing
evidence suggests that such metabolic hormones also affect
food-related sensitivity of the dopaminergic reward system [34],
pointing to an overlap between the homeostatic and reward/
reinforcement systems related to obesity [23].
Also confirming our hypothesis, the CIRCA gene set was
associated with BMI, but the absence of a significant association
with ADHD was unexpected. ADHD has previously been
associated with altered circadian rhythmicity at molecular,
endocrine, and behavior levels [35]. Furthermore, zebrafish
mutants for per1b, a key gene in circadian rhythm regulation,
and Per1-knockout mice display hyperactive, impulsivity-like, and
attention deficit-like behaviors [36]. The lack of a significant
association between ADHD and the CIRCA gene set in our study
may be due to a true lack of effect of the circadian rhythm
pathway on ADHD. However, given that some of the CIRCA genes
are among the cross-disorder(/trait) overlapping genes, it is also
possible that there is a true (unobserved) effect but that the gene
set we assembled was not appropriate/informative enough to
detect such association.
Going beyond candidate gene-set analyses, we conducted
data-driven, genome-wide ADHD–BMI and ADHD–obesity gene-
based meta-analyses. Cross-disorder(/trait) overlapping genes
were carried forward into two follow-up approaches: one testing
the association of (ADHD–BMI) overlapping genes with specific
subcortical brain volumes previously linked to these
phenotypes and the other aimed at identifying enriched
biological pathways underlying the shared heritability. Both
follow-up approaches again pointed to a role of the dopami-
nergic system. Through the first, we observed a significant
association of ADHD–BMI overlapping genes with putamen
volume in two independent samples (Table 4). This finding is of
particular interest given the strong role of the dopaminergic
system in this brain region and the prominent involvement of
the putamen in inhibitory control functioning, one of the key
neurobiological features suggested to be altered both in ADHD
and obesity [18, 19]. The second follow-up approach showed
several pathways significantly enriched in the ADHD–BMI and
ADHD–obesity results. Dopamine signaling was at the heart of
the pathway that was significantly enriched in both analyses, i.e.,
the Dopamine-DARPP32 Feedback in cAMP Signaling pathway.
This postsynaptic pathway centers around the Dopamine- and
cAMP-regulated neuronal phosphoprotein (DARPP-32; also
known as Protein phosphatase 1 regulatory subunit 1B
(PPP1R1B)), the phosphorylation state of which modulates
dopaminergic neurotransmission (see Fig. 1 and description
in Supplementary Material for details).
DARPP-32 is primarily expressed in postsynaptic dopaminergic
neurons in the dorsal striatum (i.e., brain structure that includes, in
addition to the caudate, the putamen; see results above for the
association of ADHD–BMI overlapping genes and brain volumes),
which is involved in certain executive functions, such as inhibitory
control, and in the ventral striatum, which is the main brain region
responsible for reward processing (https://gtexportal.org/home/
gene/PPP1R1B). As described above, poor inhibitory control and
altered reward processing, in the form of steeper delay discount-
ing, are key neurobiological circuitries implicated in both ADHD
and obesity [21, 23]. Further evidence linking dopamine DARPP-32
signaling, reward processing, and the brain comes from findings in
animal models. Upon investigation of the consequences of
frustrated expected reward of palatable food on gene expression
in the mouse brain, Dopamine-DARPP32 Feedback in cAMP
Signaling pathway was found to be enriched among differentially
expressed genes, both the ventral striatum and in frontal
cortex [37].
DARPP-32 modulates the effects of dopamine on cAMP/PKA-
dependent gene transcription through transcription factors of the
cyclic AMP-responsive element-binding (CREB) complex (Fig. 1),
and CREB dysregulation has been linked to both ADHD [38] and
obesity [39]. Of note, the CREB Signaling in Neurons pathway was
also significantly enriched in our ADHD–BMI gene-based meta-
analysis, along with two other partially overlapping pathways
involved in synaptic plasticity processes (namely, the Synaptic
Long Term Depression and the Synaptic Long Term Potentiation
pathways; Table 2), which are also closely related to dopamine
DARPP-32 signaling.
Additional evidence for an involvement of DARPP-32 signaling
to the ADHD–BMI/obesity overlap comes from the study of rare
variants. The most common form of monogenic obesity is caused
by mutations in the melanocortin 4 receptor (MC4R) gene [40],
and MRC4 signaling is known to activate DARPP-32 [41]. In
addition to early-onset obesity, a higher prevalence of ADHD has
been reported in MC4R mutation carriers [42]. It has been
hypothesized that such co-occurrence may be, in part,
underpinned by reward processing deficits [43], and animal
studies provide further support regarding the involvement
of MC4R signaling and dopaminergic-dependent reward proces-
sing [41].
Our study has strengths and limitations. A clear strength is that
we make use of the largest GWAS results available for each of the
phenotypes being investigated. The sample sizes used to generate
the (European ancestry) summary statistics used here were, in
total, >53,000 for the iPSYCH-PGC ADHD GWAS, up to 700,000 for
the GIANT-UK Biobank BMI GWAS, and almost 99,000 for the
GIANT obesity GWAS. Obesity measures were, therefore, assessed
both as a trait and a state. Although we performed the
(categorical) obesity analysis using GWAS data from the obesity
class with the largest sample size (obesity class I N= 32,858 cases,
N= 65,839 controls; class II N= 9889 cases, N= 62,657 controls;
class III N= 2896 cases, N= 47,468 controls; [12]), it is possible that
the quantitative nature of BMI and the much larger sample size of
the BMI GWAS provide more powerful analyses/results than with
Table 4. Gene-set association results of the set of 211 ADHD-BMI
overlapping genes with brain volumes.
Brain volume ENIGMA GWASa UK Biobank GWASb
Mean N P value P value
Main analysesc
Putamen 10,829 7.65 × 10−3 3.94 × 10−2







Significant associations are highlighted in bold
aGWAS summary statistics from the ENIGMA consortium, as described
by Hibar et al. [20]. Previous to gene-set analyses, the NeuroIMAGE cohort
(N= 154), which includes ADHD cases, was removed from the
ENIGMA data
bReplication sample—GWAS summary statistics from the UK Biobank
cohort, including N= 8428 individuals, as described by [28]
cBrain volumes previously associated with both ADHD [18] and BMI [19]
dBrain volumes associated only with ADHD or BMI [18, 19]
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the obesity GWAS class I, which may account, at least in part, for
some of the differences observed between the BMI and obesity
results. All GWAS summary statistics used here are derived from
individuals with European ancestry; the homogeneous back-
ground can be a strength given that genetic analyses can be
sensible to population stratification, but we also would like to
highlight the need of large studies on more diverse populations.
Another strength is that we did not restrict our gene set assembly
to single GO terms or KEGG pathways but applied a more inclusive
approach regarding the processes involved. For dopaminergic
neurotransmission, we thus assembled a gene set (DOPA) that was
subsequently found to be significantly associated with ADHD and
BMI. This contrasts with the approach adopted in the iPSYCH-PGC
ADHD GWAS paper, which tested dopaminergic candidate genes
and GO term pathways only individually, failing to detect
significant associations with ADHD [4]. The large difference in
sample sizes between the phenotypes imposed some difficulties
when analyzing them together. We minimized such limitations by
carrying out gene-based cross-disorder(/trait) meta-analyses in
MAGMA, which allows sample sizes to vary between and within
samples and accounts for such variation by weighting the effects
accordingly. We also opted for performing gene-based—rather
than SNP-based—cross-disorder(/trait) meta-analyses. Apart from
assuming that the (combined effect of SNPs within) genes
represent entities closer to the biological mechanisms, this
approach has a reduced statistical burden compared to SNP-
based analyses and seems most suitable for these data given the
difference in SNP density between the ADHD and the BMI and
obesity GWASs (the latter ones being restricted to about 2.4
million SNPs present in HapMap 2). An additional advantage of
using gene-based approach when meta-analyzing different
phenotypes is that it does not rely on a priori expectations of
concordance of the direction of effects, which avoids information
on loci with discordant direction of effects from being lost.
Another limitation we addressed was the presence of overlapping
samples, since Welcome Trust participants had been included
both in the iPSYCH-PGC ADHD GWAS and the GIANT BMI and
obesity GWASs. The reduction in sample size reduced power of
our analysis, but findings from the canonical pathway enrichment
analysis remained stable. Finally, despite the undeniable genetic
component of these complex disorders/traits, the current available
sample sizes and techniques applied in genome-wide studies still
only allow for a small proportion of the phenotypic variance to be
accounted for by common variants genome-wide. However, we
strongly believe that identifying the biological pathways shared
between disorders represents a promising way forward to a better
understanding of comorbidity, which goes far beyond the
observed effect sizes of specific genes/pathways and their
variance explained. Given the limitations stated above, our results
should be interpreted with caution and considered as exploratory
until more adequately powered samples and methods are
available.
Overall, the findings of the present study identify dopaminergic
neurotransmission as a key player underlying the shared
heritability of ADHD and BMI/obesity, implicating mechanisms
involving DARPP-32 signaling in particular and possibly involving
neurobiological features related to putamen, such as inhibitory
control. This is especially interesting since DARPP-32 has been
directly implicated in the mechanism of action of ADHD
medication [44], which has been suggested to attenuate the
increased risk for obesity in people with ADHD [15]. The fact that
we observe a convergence between the results from hypothesis-
driven and hypothesis-free approaches provides extra support to
the robustness of our findings. Uncovering critical aspects of the
shared etiology underlying the prevalent ADHD–obesity comor-
bidity may have important implications for clinical outcome,
preventive interventions, and/or efficient treatment of these
conditions.
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